National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

autologous dinitrophenyl-modified ovarian cancer vaccine
A cancer vaccine consisting of autologous ovarian cancer cell peptide antigens conjugated to the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of autologous dinitrophenyl-modified ovarian cancer vaccine may induce a cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:autologous DNP-modified ovarian cancer vaccine
US brand name:OVax



Previous:autologous dendritic cell-adenovirus CCL21 vaccine, autologous dendritic cell-adenovirus p53 vaccine, autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine, autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine, autologous dendritic cell-tumor fusion vaccine
Next:autologous EBV-CTL CD19CAR zeta, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine, autologous expanded mesenchymal stem cells OTI-010

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov